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Abbreviations {#feb213806-sec-0001}
=============

ACE2, angiotensin I‐converting enzyme 2

MERS, Middle East respiratory syndrome

RBD, receptor‐binding domain

SARS‐CoV, severe acute respiratory syndrome coronavirus

SBDR, structure‐based drug repositioning

WHO, World Health Organization

 {#feb213806-sec-0002}

The newly identified coronavirus (SARS‐CoV‐2) causes severe pneumonia (coronavirus disease 2019---COVID‐19) and has rapidly spread across the world from the initial outbreak point in Wuhan, China, in late 2019 \[[1](#feb213806-bib-0001){ref-type="ref"}\]. It has become a global health emergency, and on March 11, 2020, the World Health Organization (WHO) declared a pandemic status of this novel coronavirus outbreak. Since no approved drug that is specifically targeted to this virus exists at this point in time, drug repositioning/repurposing is thought to be the most effective and feasible approach toward this clear and present threat, and researchers have initiated studies by employing various means in order to find potential therapeutics \[[3](#feb213806-bib-0003){ref-type="ref"}, [4](#feb213806-bib-0004){ref-type="ref"}, [5](#feb213806-bib-0005){ref-type="ref"}, [6](#feb213806-bib-0006){ref-type="ref"}, [7](#feb213806-bib-0007){ref-type="ref"}, [8](#feb213806-bib-0008){ref-type="ref"}, [9](#feb213806-bib-0009){ref-type="ref"}, [10](#feb213806-bib-0010){ref-type="ref"}, [11](#feb213806-bib-0011){ref-type="ref"}\].

The SARS‐CoV‐2 genome is very close to that of the severe acute respiratory syndrome coronavirus (SARS‐CoV) \[[1](#feb213806-bib-0001){ref-type="ref"}\]. From the past efforts to cure RNA virus infections, including the experiences from the SARS and Middle East respiratory syndrome (MERS) epidemics, several potential target proteins and drugs have been proposed \[[12](#feb213806-bib-0012){ref-type="ref"}, [13](#feb213806-bib-0013){ref-type="ref"}\]. The 3C‐like (main) proteinase, surface glycoprotein \[[8](#feb213806-bib-0008){ref-type="ref"}\], and RNA‐dependent RNA polymerase are thought to be the most promising targets for anti‐COVID‐19 therapeutics. For example, the anti‐HIV drug lopinavir/ritonavir, which has been proposed to treat SARS \[[14](#feb213806-bib-0014){ref-type="ref"}, [15](#feb213806-bib-0015){ref-type="ref"}\], is expected to be effective toward SARS‐CoV‐2 3C‐like proteinase \[[16](#feb213806-bib-0016){ref-type="ref"}, [17](#feb213806-bib-0017){ref-type="ref"}\]. Additionally, the antiviral drug remdesivir is expected to target the RNA‐dependent RNA polymerase \[[18](#feb213806-bib-0018){ref-type="ref"}\].

The recent studies on drug repositioning/repurposing involve a variety of computational methods, such as network analysis, text mining, machine learning, and structure‐based drug repositioning (SBDR) \[[19](#feb213806-bib-0019){ref-type="ref"}, [20](#feb213806-bib-0020){ref-type="ref"}, [21](#feb213806-bib-0021){ref-type="ref"}, [22](#feb213806-bib-0022){ref-type="ref"}, [23](#feb213806-bib-0023){ref-type="ref"}, [24](#feb213806-bib-0024){ref-type="ref"}\]. Among these methods, SBDR is the most promising to find specific drugs toward a defined target protein, and it prompted the quick structure analyses of SARS‐CoV‐2 3C‐like proteinase and surface glycoprotein \[[8](#feb213806-bib-0008){ref-type="ref"}, [25](#feb213806-bib-0025){ref-type="ref"}\].

Although structure analyses of many other SARS‐CoV‐2 proteins would soon follow, predictions of other protein structures with homology/knowledge‐based (theoretical) methods would be required until structure analyses are completed, especially for the proteins currently out of focus as drug targets. In the presented study, therefore, the homology models of SARS‐CoV‐2 proteins and their ligand complexes were comprehensively constructed. Also, the structural models of the complexes between SARS‐CoV‐2 proteins and potential drugs were proposed by comparing the ligand molecules of the proteins and approved, experimental, or natural drugs.

MATERIALS AND METHODS {#feb213806-sec-0003}
=====================

Homology modeling of SARS‐CoV‐2 proteins {#feb213806-sec-0004}
----------------------------------------

The amino acid sequences of SARS‐CoV‐2 proteins (Table [1](#feb213806-tbl-0001){ref-type="table"}) were retrieved from the RefSeq database at NCBI \[[26](#feb213806-bib-0026){ref-type="ref"}\], and structural modeling templates were sought with the SIRD system (<http://sird.nagahama-i-bio.ac.jp/sird/>), which accepted multiple query sequences and sought for similar sequences (more than 30% sequence identity to query) with known structures in the Protein Data Bank (PDB) \[[27](#feb213806-bib-0027){ref-type="ref"}\] by using BLAST \[[28](#feb213806-bib-0028){ref-type="ref"}\]. This system also sought for the templates of protein complex structures, in which two or more proteins in the multiple query were associated or any ligand bound to query proteins. The coordinates of template structures were obtained from the PDB \[[27](#feb213806-bib-0027){ref-type="ref"}\] and were rendered into the biological quaternary structures.

###### 

Models of SARS‐CoV‐2 protein[^a^](#feb213806-note-0002){ref-type="fn"}.

  Gene             Protein                            Name                          Length           Model template   Model                                                                                                                                                                                        
  ---------------- ---------------------------------- ----------------------------- ---------------- ---------------- ------------------ -------------------------------------- ------------------------------------------------------- ------------------------------- --------------------- ------ ------ ------ ------
  orf1ab           YP_009725297.1                     Leader protein                180              <http://2HSX>A   85.3               66.7                                   monomer(A)                                              A: 10--129                                                   0.97   0      4.75
  YP_009725298.1   nsp2                               638                           n.a.                                                                                                                                                                                                                           
  YP_009725299.1   Papain‐like proteinase (nsp3)      1945                          <http://2IDY>A   79.3             5.9                monomer(A)                             A: 1--114                                                                                                     0.98   0      4.55   
                                                      <http://2FAV>C                72.5             9.2              monomer(A)         A: 202--379                                                                                                                    0.67                  0      4.41          
                                                      <http://2WCT>B                76.3             13.9             homo‐dimer(A, B)   A, B: 410--679                                                                                                                 1.27                  0      4.96          
                                                      <http://2KQW>A                72.7             3.7              monomer(A)         A: 675--746                                                                                                                    1.52                  0      4.41          
                                                      <http://5E6J>A                82.0             16.6             monomer(A)         A: 745--1067                                                                                                                   0.35                  0      3.71          
                                                      <http://2K87>A                81.0             6.3              monomer(A)         A: 1085--1206                                                                                                                  1.79                  0      3.58          
  YP_009725300.1   nsp4                               500                           <http://3GZF>A   40.0             20.4               homo‐dimer(A, B)                       A: 399--500 B: 399--497                                                                                       1.69   0      3.43   
  YP_009725301.1   3C‐like proteinase                 306                           <http://6LU7>A   100.0            100.0              homo‐dimer(A, C)                       A, C: 1--306                                                                            AZP, Carfilzomib      0      0      4.54   
  YP_009725302.1   nsp6                               290                           n.a.                                                                                                                                                                                                                           
  YP_009725303.1   nsp7                               83                            <http://2KYS>A   98.8             100.0              monomer(A)                             A: 1--83                                                                                                      1.3    0      4.57   
  YP_009725304.1   nsp8                               198                           <http://2AHM>H   97.4             98.5               hetero‐16mer(E, F, G, H, S, T, U, V)   E, S: 35--195 F, T: 47--195 G, U: 1--194 H, V: 1--195   nsp7 (A, B, C, D, O, P, Q, R)                         1.08   0      4.42   
  YP_009725305.1   nsp9                               113                           <http://1UW7>A   97.3             100.0              homo‐dimer(A, B)                       A, B: 1--113                                                                                                  1.6    0      4.86   
  YP_009725306.1   nsp10                              139                           <http://5NFY>H   98.5             96.4               hetero‐dimer(B)                        B: 1--134                                               3\'‐to‐5\' exonuclease (A)      ZN                    1.23   0      4.78   
  YP_009725307.1   RNA‐dependent RNA polymerase       932                           <http://6NUR>A   96.3             86.8               hetero‐tetramer(A)                     A: 114--922                                             nsp8 (B, D), nsp7(C)            ZN                    0.81   0      4.87   
  YP_009725308.1   Helicase                           601                           <http://5WWP>A   71.5             99.7               monomer(A)                             A: 1--599                                                                               ZN                    1.54   0      4.82   
  YP_009725309.1   3\'‐to‐5\' Exonuclease             527                           <http://5NFY>D   94.7             100.0              hetero‐dimer(A)                        A: 1--527                                               nsp10 (B)                       ZN                    1.23   0      4.78   
  YP_009725310.1   Endo‐RNAse                         346                           <http://2H85>A   88.1             100.0              homo‐hexamer(A, B, C, D, E, F)         A, B, C, D, E, F: 1--346                                                                                      0.92   0      4.75   
  YP_009725311.1   2\'‐*O*‐Ribose methyltransferase   298                           <http://5YNI>A   66.3             100.0              hetero‐dimer(A)                        A: 1--298                                               nsp10 (B)                       GTG, ZN, Sinefungin   1.66   0      4.69   
                                                                                                                                                                                                                                        GTG, ZN, Tecadenoson            1.66                  0      4.55          
                                                                                                                                                                                                                                        GTG, ZN, Selodenoson            1.39                  0      4.55          
                                                                                                                                                                                                                                        GTG, ZN, Trabodenoson           1.39                  0      4.40          
  YP_009725312.1   nsp11                              13                            n.a.                                                                                                                                                                                                                           
  S                YP_009724390.1                     Surface glycoprotein          1273             <http://6VSB>A   100.0              88.6                                   homo‐trimer(A, B, C)                                    A, B, C: 13--1140               ACE2 (D)              EAL    1.75   0.08   5.58
                                                                                                                                                                                                                                                                                              LPR    1.72   0.08   5.58
                                                                                                                                                                                                                                                                                              X8Z    1.72   0.08   5.60
  ORF3a            YP_009724391.1                     ORF3a protein                 275              n.a.                                                                                                                                                                                                          
  E                YP_009724392.1                     Envelope protein              75               <http://5X29>E   91.4               90.7                                   homo‐pentamer(A, B, C, D, E)                            A, C, D, E: 5--68 B: 1--68                                   1.67   0      4.63
  M                YP_009724393.1                     Membrane glycoprotein         222              n.a.                                                                                                                                                                                                          
  ORF6             YP_009724394.1                     ORF6 protein                  61               n.a.                                                                                                                                                                                                          
  ORF7a            YP_009724395.1                     ORF7a protein                 121              <http://1YO4>A   88.4               75.2                                   monomer(A)                                              A: 11--101                                                   0      0      4.92
  ORF7b            YP_009725296.1                     ORF7b                         43               n.a.                                                                                                                                                                                                          
  ORF8             YP_009724396.1                     ORF8 protein                  121              n.a.                                                                                                                                                                                                          
  N                YP_009724397.2                     Nucleocapsid phosphoprotein   419              <http://1SSK>A   81.6               39.1                                   monomer(A)                                              A: 20--183                                                   1.56   0      4.88
                                                                                                     <http://2JW8>B   95.8               30.1                                   homo‐dimer(A, B)                                        A: 243--367 B: 242--367                                      0.48   0      3.31
  ORF10            YP_009725255.1                     ORF10 protein                 38               n.a.                                                                                                                                                                                                          

'Protein' indicates RefSeq IDs of SARS‐CoV‐2 proteins and also serves as the model identifiers. 'Model template': 'Identity' and 'Coverage' show amino acid sequence identity and coverage of the template structure ('PDB ID') to the corresponding SARS‐CoV‐2 proteins. 'Model': 'Model description' and 'Interacting protein' show chain ID(s) of the corresponding and bounding proteins, respectively. 'Region' shows chain ID(s) and the start and end residue numbers of modeled region. 'Ligand' shows the names or PDB codes of ligands in the template or model structures. 'Rotamer outlier', 'Ramachandran outlier', and 'Clash score' show the parameters of the models.
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Initial structural models were constructed by using [modeller]{.smallcaps} \[[29](#feb213806-bib-0029){ref-type="ref"}\]. In some cases, the resultant models contain residues with rare dihedral angles (Ramachandran outliers), rare shape of side chains (rotamer outliers), and short atom--atom distances (atomic crashes). Then, the models were further modified by iteratively applying molecular dynamics and geometry minimization procedures of [phenix]{.smallcaps} \[[30](#feb213806-bib-0030){ref-type="ref"}\] to eliminate aforementioned outliers, and finally, manual model modifications with visual inspection on COOT for resolving rotamer outliers or atomic crashes \[[31](#feb213806-bib-0031){ref-type="ref"}\]. The model quality was evaluated with [molprobity]{.smallcaps} \[[32](#feb213806-bib-0032){ref-type="ref"}\]. The percentages of rotamer outlier, Ramachandran outlier, and crash score were monitored for each model to achieve less than 2%, 0.05%, and 5, respectively.

Modeling of SARS‐CoV‐2 protein complexes with potential drugs {#feb213806-sec-0005}
-------------------------------------------------------------

The molecular formula of 8,085 drugs in total was retrieved from the KEGG database \[[33](#feb213806-bib-0033){ref-type="ref"}\] and the DrugBank database \[[34](#feb213806-bib-0034){ref-type="ref"}\]. The molecular formula of 5,780 metabolites in total, which have been used for natural medicines (natural drugs), was obtained from the KNApSAcK database \[[35](#feb213806-bib-0035){ref-type="ref"}\].

The structures of the ligand molecules in the known complex structures, as sought in the template search process, were exhaustively compared with that of the drugs by using COMPLIG \[[36](#feb213806-bib-0036){ref-type="ref"}\]. COMPLIG matches molecular graphs and evaluates the similarity score of two molecules A and B as min{M(A, B)/M(A), M(A, B)/M(B)}, where M(A) and M(B) are the total numbers of atoms and bonds in molecules A and B, respectively, and M(A, B) is the total number of atoms and bonds matched between molecules A and B. Both element and chirality, if applicable, should be identical for atoms, and bond order should be identical for bonds to be matched.

Selected drug molecules were built into the protein models by superposing drug molecules to known (original) ligand molecules with COMPLIG. According to the graph matching results, the dihedral angles in the drug molecules were adjusted toward the corresponding angles in the original ligand molecules, and corresponding atoms were superposed between drug and known ligand by fixing the coordinates of the latter. The models of protein--drug complexes were further modified with PHENIX and COOT. The constraints for drug molecules were generated by using the eLBOW application in PHENIX. Hydrogen bonds were evaluated with canonical parameters (constraints were relaxed by 0.4 Å and 20 degrees) \[[37](#feb213806-bib-0037){ref-type="ref"}\] by using CHIMERA \[[38](#feb213806-bib-0038){ref-type="ref"}\]. The protein--ligand complexes were also assessed by using the DSX score function \[[39](#feb213806-bib-0039){ref-type="ref"}\].

RESULTS {#feb213806-sec-0006}
=======

Models of SARS‐CoV‐2 protein {#feb213806-sec-0007}
----------------------------

The SARS‐CoV‐2 genome encodes 11 genes (open reading frames), and the polyprotein from orf1ab is processed into 16 proteins (polypeptides) through cleavages by the papain‐like proteinase and 3C‐like proteinase activities \[[1](#feb213806-bib-0001){ref-type="ref"}, [12](#feb213806-bib-0012){ref-type="ref"}, [40](#feb213806-bib-0040){ref-type="ref"}\]. As a result of template search, the appropriate structural templates were found for 17 SARS‐CoV‐2 proteins among a total of 26, and their homology models were constructed (Table [1](#feb213806-tbl-0001){ref-type="table"}). The 9 unmodeled proteins included those from very short ORFs, namely Nsp11 (13 amino acid residues), ORF7b (43 residues), and ORF10 (38 residues) and probable membrane proteins (nsp6, ORF3a, ORF6, M, and ORF8), which were annotated by the SOSUI server \[[41](#feb213806-bib-0041){ref-type="ref"}\].

Since a considerable amount of structural studies have already been done for SARS‐CoV and MERS‐CoV proteins, most of the available templates were from these viruses, and they had high‐sequence similarity (more than 90%) to SARS‐CoV‐2 proteins. Two proteins, namely papain‐like proteinase (nsp3) and nucleocapsid phosphoprotein, could not be modeled into a single structural model. As a result of homology search, template structures covering the entire protein were unavailable. Template structures were separated into 6 and 2 fragment/domain models, respectively. Consequently, the coverages of structural model were 56% and 69% of total residues for papain‐like proteinase (nsp3) and nucleocapsid phosphoprotein, respectively (Table [1](#feb213806-tbl-0001){ref-type="table"}).

The third region of papain‐like proteinase (nsp3), nsp4, 3C‐like proteinase, nsp9, endo‐RNAse, surface glycoprotein, envelope protein, and C‐terminal region of nucleocapsid phosphoprotein was modeled into homo‐multimer. As the hetero‐multimeric models, nsp7 and nsp8 were modeled into hetero‐16mer; RNA‐dependent RNA polymerase, nsp7, and nsp8 were modeled as hetero‐tetramer (1:1:2 stoichiometry); 3\'‐to‐5\' exonuclease and nsp10 formed hetero‐dimer; 2\'‐*O*‐ribose methyltransferase and nsp10 also formed hetero‐dimer; and homo‐trimer of surface glycoprotein was modeled in complex with human angiotensin I‐converting enzyme 2 (ACE2) (Table [1](#feb213806-tbl-0001){ref-type="table"}).

Models of SARS‐CoV‐2 protein with drug {#feb213806-sec-0008}
--------------------------------------

Although the models of SARS‐CoV‐2 protein would be useful for structure‐based virtual screening, potential drugs for these proteins were sought by rather simple knowledge‐based method in the presented study. The ligand molecules that were complexed with the homologs of SARS‐CoV‐2 protein in the PDB were extracted, and structurally similar molecules to the ligands were sought among the approved/experimental drugs retrieved from the KEGG database \[[33](#feb213806-bib-0033){ref-type="ref"}\] and the DrugBank database \[[34](#feb213806-bib-0034){ref-type="ref"}\]. Many of the approved drugs, such as morphine, aspirin, or penicillin, have been adapted from natural medicines \[[42](#feb213806-bib-0042){ref-type="ref"}, [43](#feb213806-bib-0043){ref-type="ref"}\]. The molecules in the natural medicines are expected to serve as argent therapeutics. Therefore, the ligand structures were also compared with the components of natural medicines (natural drugs) registered in the KNApSAcK database \[[35](#feb213806-bib-0035){ref-type="ref"}\].

The original ligand molecules and the detected drug molecules are summarized in Table [2](#feb213806-tbl-0002){ref-type="table"}. A total of 11 ligand molecules were matched to 21 approved/experimental and 5 natural drugs, and the complex models of the SARS‐CoV‐2 proteins with several promising drugs, those with high similarity score or placed in higher ranking, were constructed as follows.

###### 

Potential drugs for SARS‐CoV‐2[^a^](#feb213806-note-0003){ref-type="fn"}.

  Ligand name                                                                                                                                                Ligand code               Protein name                               Protein sources                               PDB IDs                                                                     Score   Drug name            DB codes
  ---------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ------------------------------------------ --------------------------------------------- --------------------------------------------------------------------------- ------- -------------------- -------------------
  *S*‐adenosyl‐[l]{.smallcaps}‐methionine                                                                                                                    SAM                       2\'‐*O*‐Ribose methyltransferase (nsp16)   SARS‐CoV, human betacoronavirus 2C EMC/2012   <http://5C8T>, <http://3R24>, <http://5YNI>, <http://5YNM>, <http://5YN6>   1.000   Ademetionine         D07128
  0.946                                                                                                                                                      Sinefungin                C00052045, D05846                                                                                                                                                                                 
  0.862                                                                                                                                                      Tecadenoson               D06019                                                                                                                                                                                            
  0.814                                                                                                                                                      Selodenoson               D05818                                                                                                                                                                                            
  0.814                                                                                                                                                      Trabodenoson              D10493                                                                                                                                                                                            
  Sinefungin                                                                                                                                                 SFG                       2\'‐*O*‐Ribose methyltransferase (nsp16)   SARS‐CoV, human betacoronavirus 2C EMC/2012   <http://2XYR>, <http://5YNN>, <http://5YNP>, <http://5YNB>                  1.000   Sinefungin           C00052045, D05846
  0.946                                                                                                                                                      Ademetionine              D07128                                                                                                                                                                                            
  0.862                                                                                                                                                      Tecadenoson               D06019                                                                                                                                                                                            
  0.832                                                                                                                                                      Adenosine monophosphate   D02769                                                                                                                                                                                            
  0.832                                                                                                                                                      Selodenoson               D05818                                                                                                                                                                                            
  7‐Methyl‐Guanosine‐5\'‐Triphosphate‐5\'‐Guanosine                                                                                                          GTG                       2\'‐*O*‐Ribose methyltransferase           Human betacoronavirus 2C EMC/2012             <http://5YNI>, <http://5YNN>                                                0.788   Nadide               D00002
  0.763                                                                                                                                                      Diquafosol tetrasodium    D03864                                                                                                                                                                                            
  Ace‐Ser‐Ala‐Val‐ALC‐His‐H                                                                                                                                  n.a                       3C‐like proteinase                         SARS‐CoV                                      <http://3AVZ>                                                               n.d.                         
  N‐\[(5‐methylisoxazol‐3‐yl)carbonyl\]alanyl‐L‐valyl‐N \~ 1‐((1R,2Z)‐4‐(benzyloxy)‐4‐oxo‐1‐{\[(3R)‐2‐oxopyrrolidin‐3‐yl\]methyl}but‐2‐enyl)‐L‐leucinamide   n.a                       3C‐like proteinase                         SARS‐CoV‐2                                    <http://6LU7>                                                               n.d.                         
  C4Z inhibitor                                                                                                                                              n.a                       3C‐like proteinase                         SARS‐CoV                                      <http://3VB5>                                                               n.d.                         
  Ac‐ESTLQ‐H                                                                                                                                                 n.a                       3C‐like proteinase                         SARS‐CoV                                      <http://3SND>                                                               0.783   Magnesium pidolate   D08263
  0.779                                                                                                                                                      Decanal                   C00030099                                                                                                                                                                                         
  0.779                                                                                                                                                      1‐Decanol                 C00030100                                                                                                                                                                                         
  0.775                                                                                                                                                      Undecanal                 C00032442                                                                                                                                                                                         
  (5s,8s,14r)‐Ethyl 11‐(3‐Amino‐3‐ Oxopropyl)‐8‐Benzyl‐14‐Hydroxy‐5‐Isobutyl‐3,6,9,12‐Tetraoxo‐1‐Phenyl‐2‐Oxa‐4,7,10,11‐Tetraazapentadecan‐15‐Oate           AZP                       3C‐like proteinase                         SARS‐CoV                                      <http://2GTB>                                                               0.754   Carfilzomib          D08880
  1‐((2S)‐2‐{\[(1S)‐1‐Carboxy‐3‐Phenylpropyl\]Amino}Propanpyl)‐L‐Proline                                                                                     EAL                       ACE                                        Human                                         <http://1UZE>                                                               1.000   Enalaprilat          D03769
  0.932                                                                                                                                                      Lisinopril                D00362                                                                                                                                                                                            
  0.926                                                                                                                                                      Enalaprilat               D00621                                                                                                                                                                                            
  0.925                                                                                                                                                      Spiraprilat               D03775                                                                                                                                                                                            
  0.918                                                                                                                                                      Lisinopril                D00362                                                                                                                                                                                            
  \[*N*2‐\[(*S*)‐1‐Carboxy‐3‐phenylpropyl\]‐L‐lysyl‐L‐proline                                                                                                LPR                       ACE somatic isoform                        Human                                         <http://1O86>                                                               1.000   Lisinopril           D00362
  0.932                                                                                                                                                      Enalaprilat               D03769                                                                                                                                                                                            
  0.896                                                                                                                                                      Enalaprilat               D07892                                                                                                                                                                                            
  0.867                                                                                                                                                      Ceronapril                D03440                                                                                                                                                                                            
  0.857                                                                                                                                                      Spiraprilat               D03775                                                                                                                                                                                            
  L‐Captopril                                                                                                                                                X8Z                       ACE                                        Human                                         <http://4C2P>                                                               1.000   Captopril            D00251
  0.853                                                                                                                                                      Telmesteine               D08565                                                                                                                                                                                            
  0.851                                                                                                                                                      Oxaceprol                 D07215                                                                                                                                                                                            
  0.795                                                                                                                                                      Undecanoic acid           C00007421                                                                                                                                                                                         
  0.795                                                                                                                                                      Bucillamine               D01809                                                                                                                                                                                            

'Protein source' and 'PDB ID' are the source organisms and PDB of the template structures, respectively. 'Ligand code' is HETATM code in PDB. 'DB code' is headed by D and C for the IDs of the molecules in KEGG and KNApSAcK, respectively. 'Score' indicates the similarity score of each drug molecule in KEGG or KNApSAcK to the ligand in the template structures computed by COMPLIG (see [Materials and methods](#feb213806-sec-0002){ref-type="sec"}).
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3C‐like proteinase {#feb213806-sec-0009}
------------------

3C‐like proteinase is involved in the processing of viral polyprotein \[[44](#feb213806-bib-0044){ref-type="ref"}\]. This enzyme is one of the most extensively studied drug targets and thus analyzed in complex with various peptide mimetic inhibitors \[[45](#feb213806-bib-0045){ref-type="ref"}, [46](#feb213806-bib-0046){ref-type="ref"}, [47](#feb213806-bib-0047){ref-type="ref"}, [48](#feb213806-bib-0048){ref-type="ref"}\]. Unexpectedly, these ligands did not show very high similarity to known drug molecules (Table [2](#feb213806-tbl-0002){ref-type="table"}). As a peptide mimetic drug, carfilzomib showed highest score to the template ligand (ligand code AZP) of 3C‐like proteinase homolog (Fig. [1A](#feb213806-fig-0001){ref-type="fig"}). However, the similarity score between the ligand and the drug was only 0.754. Carfilzomib is the irreversible proteasome inhibitor targeted to the subunits with chymotrypsin‐like activity and has been approved for refractory multiple myeloma or Waldenström\'s macroglobulinemia \[[49](#feb213806-bib-0049){ref-type="ref"}, [50](#feb213806-bib-0050){ref-type="ref"}\]. A complex model of carfilzomib--SARS‐CoV‐2 3C‐like proteinase was constructed. In the model, carfilzomib formed a parallel β‐sheet with His164--Glu166, and side chains of His41, Cys145, Met165, Leu167, Phe185, and Gln189 contributed major interactions (Fig. [1B,C](#feb213806-fig-0001){ref-type="fig"}). These residues were conserved between the template (SARS‐CoV) and the model (SARS‐CoV‐2) proteins. Carfilzomib covalently binds to active site threonine through epoxy moiety, and the epoxy moiety is also reactive with thiol group of cysteine. Although a possible covalent linkage between carfilzomib and the catalytic Cys145 of SARS‐CoV‐2 3C‐like proteinase was not explicitly modeled, the epoxy moiety was placed close to the catalytic residue in this model. The fitness of the ligand to SARS‐CoV‐2 3C‐like proteinase in the model was evaluated by the DSX function, and the score of carfilzomib, --139.6, was even better than that (−99.8) of inhibitor N3 in the complex crystal structure of SARS‐CoV‐2 3C‐like proteinase (PDB ID <http://6LU7>).

![3C‐like proteinase--carfilzomib model. (A) Formula of (5s, 8s, 14r)‐ethyl 11‐(3‐amino‐3‐oxopropyl)‐8‐benzyl‐14‐hydroxy‐5‐isobutyl‐3, 6, 9, 12‐tetraoxo‐1‐phenyl‐2‐oxa‐4, 7, 10, 11‐tetraazapentadecan‐15‐oate (template ligand with ligand code AZP), carfilzomib, and lopinavir/ritonavir. (B) Overall structure of the model. (C) Close view of the carfilzomib binding site. Hydrogen bonds are shown in yellow lines.](FEB2-9999-na-g001){#feb213806-fig-0001}

Surface glycoprotein--ACE2 complex {#feb213806-sec-0010}
----------------------------------

Surface glycoprotein is used for a viral entrance into the host cell, and its cell surface receptor is human angiotensin I‐converting enzyme 2 (ACE2) \[[51](#feb213806-bib-0051){ref-type="ref"}\]. ACE, a homolog of ACE2 sharing 44% amino acid sequence identity, is a major target of hypertension medicating drugs, and several ACE--drug complexes have been reported \[[52](#feb213806-bib-0052){ref-type="ref"}, [53](#feb213806-bib-0053){ref-type="ref"}, [54](#feb213806-bib-0054){ref-type="ref"}\]. Lisinopril, enalaprilat, and captopril, which show similar structures to each other (Fig. [2A](#feb213806-fig-0002){ref-type="fig"}), have been targeted toward ACE and approved for hypertension treatments \[[55](#feb213806-bib-0055){ref-type="ref"}, [56](#feb213806-bib-0056){ref-type="ref"}, [57](#feb213806-bib-0057){ref-type="ref"}, [58](#feb213806-bib-0058){ref-type="ref"}\]. In the structural complex models, these drugs were bound to the protein through a Zn^2+^ coordination with Glu384, His356, and His360 (Fig. [2B,C](#feb213806-fig-0002){ref-type="fig"}). These residues were conserved between the template (ACE) and the model (ACE2) structures. The drug molecules also formed electrostatic interactions with Arg255 and Arg500 even though these residues were not conserved between ACE and ACE2 (Gln259 and Ser504 in ACE). The SARS‐CoV‐2 surface glycoprotein interacted with ACE2 through the receptor‐binding domain (RBD), while the bound drugs had no direct interaction to the RBD (Fig. [2C](#feb213806-fig-0002){ref-type="fig"}), suggesting that those drugs would not directly interfere the host--pathogen interaction.

![Surface glycoprotein--ACE2--lisinopril/enalaprilat/captopril model. (A) Formula of lisinopril (ligand code LPR), enalaprilat (EAL), and captopril (X8Z). (B) Overall structure of the model. (C) Close view of the lisinopril/enalaprilat/captopril binding site. Hydrogen bonds are shown in yellow lines. Lisinopril, enalaprilat, and captopril were superposed, and the carbon atoms were colored light blue, gray, and magenta, respectively.](FEB2-9999-na-g002){#feb213806-fig-0002}

The DSX scores for lisinopril, enalaprilat, and captopril in the models were −32.7, −43.6, and −25.0, respectively. These scores were considerably inferior to that (−74.6) of the specific inhibitor MLN‐4760 in the crystal structure of human ACE2 complex (PDB ID <http://1R4L>) \[[59](#feb213806-bib-0059){ref-type="ref"}\].

2'‐O‐Ribose methyltransferase {#feb213806-sec-0011}
-----------------------------

The complex of 2'‐*O*‐ribose methyltransferase (nsp16) and nsp10 is involved in the modification of the viral RNA caps \[[60](#feb213806-bib-0060){ref-type="ref"}\]. The structure of 2'‐*O*‐ribose methyltransferase subunit was determined in complex with *S*‐adenosyl‐[l]{.smallcaps}‐methionine (ligand code SAM), 7‐methyl‐guanosine‐5\'‐triphosphate‐5\'‐guanosine (GTG), and sinefungin (SFG) \[[61](#feb213806-bib-0061){ref-type="ref"}, [62](#feb213806-bib-0062){ref-type="ref"}, [63](#feb213806-bib-0063){ref-type="ref"}\]. Among these ligands, *S*‐adenosyl‐[l]{.smallcaps}‐methionine is used for a therapeutic against depression, liver disorders, fibromyalgia, and osteoarthritis \[[64](#feb213806-bib-0064){ref-type="ref"}\], but also is an authentic substrate for this enzyme. Sinefungin is a natural drug produced by *Streptomyces griseolus* and experimentally used as antibiotics \[[65](#feb213806-bib-0065){ref-type="ref"}, [66](#feb213806-bib-0066){ref-type="ref"}, [67](#feb213806-bib-0067){ref-type="ref"}\] (Fig. [3A](#feb213806-fig-0003){ref-type="fig"}).

![2′‐*O*‐Ribose methyltransferase (nsp16)--nsp10--sinefungin/tecadenoson/ selodenoson/trabodenoson model. (A) Formula of sinefungin (ligand code SFG), tecadenoson, selodenoson, and trabodenoson. (B) Overall structure of the model. (C) Close view of the binding site for sinefungin (SFG) and trabodenoson. Hydrogen bonds are shown in yellow lines.](FEB2-9999-na-g003){#feb213806-fig-0003}

The residues of 2'‐*O‐*ribose methyltransferase, Ser74, Asp99, Asn101, Asp130, and Met131, were involved in the major interactions with sinefungin (Fig. [3B,C](#feb213806-fig-0003){ref-type="fig"}). These residues were conserved among the template proteins (SARS‐CoV and betacoronavirus) and SARS‐CoV‐2.

As the drugs similar to these ligands, several investigational adenosine A1 receptor agonists, namely tecadenoson, selodenoson, and trabodenoson, were found (Fig. [3A](#feb213806-fig-0003){ref-type="fig"}). These molecules share adenosine moiety, and this moiety interacts with the aforementioned 5 conserved residues in the complex models. The DSX scores of sinefungin, tecadenoson, selodenoson, and trabodenoson were −75.6, −54.3, −70.0, and −55.3, respectively. The scores of sinefungin and selodenoson were comparable to that (−74.9) of the genuine substrate, *S*‐adenosyl‐[l]{.smallcaps}‐methionine, in the complex crystal structure with MERS‐CoV 2'‐*O*‐ribose methyltransferase (PDB ID <http://5YNI>).

DISCUSSION {#feb213806-sec-0012}
==========

In the presented study, knowledge‐based models of SARS‐CoV‐2 proteins were constructed by homology modeling and comparison of the known ligands with drugs. Since a considerable number of structure analyses have already reported for coronavirus proteins including those of SARS‐CoV, 66% (17/26) of the SARS‐CoV‐2 proteins could be modeled based on highly similar (85% sequence identity and 89% coverage on average) templates (Table [1](#feb213806-tbl-0001){ref-type="table"}).

Several drugs were suggested to bind to the SARS‐CoV‐2 targets (Table [2](#feb213806-tbl-0002){ref-type="table"}). The procedure employed in the presented study should largely limit the extent of search (because it depends on the presence of ligands in known complex structures). However, it is noteworthy that the binding of suggested drugs to the homologous proteins of the SARS‐CoV‐2 targets would be probable because of the presence of structural evidences.

The complex models were constructed for several high‐scored and/or high‐ranked drugs. Unexpectedly, no drug was detected for one of the most promising drug targets, 3C‐like proteinase, with a similarity score higher than 0.8. In the previous study, the score more than 0.8 was suggested to be required for highly similar interactions between ligand and protein \[[36](#feb213806-bib-0036){ref-type="ref"}\]. It is implied that the inhibitors bound to the 3C‐like proteinase in the known structures are considerably deviated from most of the approved protease‐targeted drugs. For example, the anti‐HIV drug lopinavir/ritonavir, which was expected to target SARS‐CoV‐2 3C‐like proteinase \[[16](#feb213806-bib-0016){ref-type="ref"}, [17](#feb213806-bib-0017){ref-type="ref"}\], showed only limited similarity (score 0.513) to the known ligand (ligand code AXP) of SARS‐CoV 3C‐like proteinase (Fig. [2A](#feb213806-fig-0002){ref-type="fig"}). One possible reason for the low similarity to drugs is that the protease inhibitors tend to have higher molecular weight and thus their molecular structures showed large variety. Another reason would be that a majority of the protease inhibitory drugs are targeted toward serine or zinc proteases \[[68](#feb213806-bib-0068){ref-type="ref"}, [69](#feb213806-bib-0069){ref-type="ref"}\]. Also, the expected drug lopinavir/ritonavir has been designed for HIV protease, which is aspartic protease. These proteases are structurally distinct from 3C‐like proteinase known to be a cysteine protease. This observation implies that structure optimizations would likely be required for repurposed drugs for SARS‐CoV‐2 3C‐like proteinase. Consequently, the presented study suggested carfilzomib, which has been targeted toward threonine protease and approved for multiple myeloma treatment \[[49](#feb213806-bib-0049){ref-type="ref"}, [50](#feb213806-bib-0050){ref-type="ref"}\], as a marginally resembling drug. The model showed, however, carfilzomib fits well (even better than the specific inhibitor N3, according to the DSX score) into the active site by forming considerable stabilizing interactions and no severe steric hindrance (Fig. [1C](#feb213806-fig-0001){ref-type="fig"}).

Another potential target is the complex of surface glycoprotein and ACE2 to prevent virus entry into the cell \[[70](#feb213806-bib-0070){ref-type="ref"}, [71](#feb213806-bib-0071){ref-type="ref"}\]. Many hypertension drugs are targeted to ACE, and the presented study highlighted the approved drugs, namely lisinopril, enalaprilat, and captopril, as potential ligands for ACE2. An expectation in advance was to find a drug that bound to ACE2 and also interfered the interactions between surface glycoprotein and ACE2. However, as the models revealed, the drug‐binding site of ACE2 existed inside a deep cleft in the center of ACE2 molecule, and the ligands do not interact directly with the surface glycoprotein (Fig. [2C](#feb213806-fig-0002){ref-type="fig"}).

The human ACE2 has been demonstrated to change its conformation from open to close forms (PDB IDs <http://1R4L> and <http://1R42>, respectively) upon inhibitor binding \[[59](#feb213806-bib-0059){ref-type="ref"}\]. Thus, if this conformational change involves the interface to the RBD of surface glycoprotein, a drug bound to the drug‐binding site might interfere with the binding between ACE2 and surface glycoprotein indirectly. This allosteric inhibition mechanism, however, is not highly expected because no obvious conformational change was observed in the interface region when comparing the open and close conformations of ACE2. Most of the predicted drugs are targeted toward ACE (not ACE2), and ACE and ACE2 diverge considerably in their amino acid sequences (44% identity). The fitness of the drugs was evaluated to be lower than the specific inhibitor to ACE2. Therefore, effects of the predicted ACE drugs on preventing surface glycoprotein--ACE2 interactions would not be highly promising.

Another target presented results highlighted was 2'‐*O*‐ribose methyltransferase (nsp16)--nsp10 complex, which is less focused as a target of drug repurposing. 2'‐*O*‐ribose methyltransferase is required to finalize the cap structure, ^7Me^GpppA~2\'OMe~, of coronavirus RNAs by transferring a methyl group to 2' OH group of ribonucleotide from *S*‐adenosyl‐[l]{.smallcaps}‐methionine \[[72](#feb213806-bib-0072){ref-type="ref"}, [73](#feb213806-bib-0073){ref-type="ref"}\]. The cap structure is essential for viral mRNAs to be translated and escape from innate immune system in the host cell. Thus, inhibition of this enzyme might prevent virus propagation. Despite the overall sequence identities between templates (SARS‐CoV or human betacoronavirus) and SARS‐CoV‐2 enzymes were relatively low (\~66%), the residues interacting with the drugs were conserved.

Among the suggested drugs for this enzyme, sinefungin is a naturally occurring and verified inhibitor of 2'‐*O*‐ribose methyltransferase. Since a toxicity was detected \[[74](#feb213806-bib-0074){ref-type="ref"}\], however, appreciation of this natural drug should be carefully considered. Although tecadenoson has been examined in a clinical trial for atrial fibrillation, and passed phase II test, final results were not formally reported at this point of time \[[75](#feb213806-bib-0075){ref-type="ref"}\]. Trabodenoson was designed for treating ocular hypertension and primary open‐angle glaucoma \[[76](#feb213806-bib-0076){ref-type="ref"}\], but had failed in the phase III clinical trial test due to lack of superiority over placebo. Selodenoson was designed to control heart rate \[[77](#feb213806-bib-0077){ref-type="ref"}\], and it seems still in a developmental stage. Since tecadenoson and trabodenoson appeared to have cleared the phase I tests, these drugs would worth examining against COVID‐19. The DSX score suggested the fitness of sinefungin or selodenoson is comparable to the genuine substrate of the 2'‐*O*‐ribose methyltransferase.

Several structure determinations of SARS‐CoV‐2 proteins, for example, endo‐RNase (PDB IDs <http://6VWW> and <http://6VW01>), nucleocapsid phosphoprotein (<http://6VYO>), and nsp12 (RNA‐dependent RNA polymerase)‐nsp7‐nsp8 complex (PDB ID <http://7BV2>) have been reported after the modeling of the presented study was executed. Although many of the other proteins should be under analyses undoubtedly, it would take considerable time before all structures of potential targets are experimentally elucidated. During the period until the structural determinations, theoretical models might be useful. The presented structural models are freely available from the BINDS webpage (<https://www.binds.jp/SARS-CoV-2/>) and also deposited in the BSM‐Arc repository (BSM00015) \[[78](#feb213806-bib-0078){ref-type="ref"}\].
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